Compare PepsiCo, Inc. (PEP) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Sana Biotechnology Inc — how do they compare? PepsiCo, Inc. trades at $135.84 (market cap $184.26B), while Sana Biotechnology Inc trades at $3.13 (market cap $879.40M). The key difference: PepsiCo, Inc. is far larger — about 209.5× Sana Biotechnology Inc's market cap, and PepsiCo, Inc. pays a 4.39% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| PEP | SANA | |
|---|---|---|
Market Cap | $184.26B | $879.40M |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $5.92 |
52-Week Low | $134.98 | $2.68 |
Enterprise Value | $226.76B | $853.59M |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $134.98, down 0.35% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and it has beaten EPS estimates in the last three quarters. Recent news highlights price cuts on snacks like Doritos after consumer pushback and the termination of a music festival sponsorship.
The outlook is mixed: analyst consensus is a buy with a $158.79 price target, but near-term risks include competitive pressures and execution of the North American turnaround. Earnings growth and margin expansion from cost initiatives remain key catalysts for upside, though high valuation ratios and debt levels warrant caution.
SANA Biotechnology trades at $3.14, down 0.32% with a bearish technical signal. The company shows negative profitability metrics with ROE at -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve significantly in 2026. Recent positive developments include NEJM publication of groundbreaking diabetes data and multiple conference presentations highlighting clinical progress.
While analyst sentiment remains strongly bullish (82% buy ratings), the stock faces fundamental challenges with significant losses and high P/B ratio of 7.33. Investment opportunity lies in clinical pipeline advancements, but risks include ongoing cash burn and execution challenges in bringing therapies to market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
